{"id":"hpp2201","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HPP2201 activates glucagon-like peptide-1 (GLP-1) receptors, which enhance insulin secretion in response to glucose, slow gastric emptying, and promote satiety. The long-acting formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists, improving patient compliance while maintaining sustained metabolic benefits.","oneSentence":"HPP2201 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:25.958Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Obesity or weight management"}]},"trialDetails":[{"nctId":"NCT05656092","phase":"PHASE3","title":"A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2023-03-06","conditions":"Gastric Ulcer","enrollment":199}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HPP2201","genericName":"HPP2201","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HPP2201 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. Used for Type 2 diabetes mellitus, Obesity or weight management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}